Analysis of the Synergistic Antifungal Activity of Everolimus and Antifungal Drugs Against Dematiaceous Fungi

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2023 Mar 13

PMID 36909734

Authors

Lulu An

Gengpei Jia

Jingwen Tan

Lianjuan Yang

Yuemei Wang

Lei Li

Affiliations

Soon will be listed here.

Abstract

Introduction: Chromoblastomycosis (CBM) is a form of chronic mycosis that affects the skin and mucous membranes and is caused by species of dematiaceous fungi including Exophiala spp., Phialophora spp., and Fonsecaea spp. The persistence of this disease and limitations associated with single-drug treatment have complicated efforts to adequately manage this condition.

Methods: In this study, a microdilution assay was used to explore the synergistic antifungal activity of everolimus (EVL) in combination with itraconazole (ITC), voriconazole (VRC), posaconazole (POS), and amphotericin B (AMB) against a range of clinical dematiaceous fungal isolates.

Results: These analyses revealed that the EVL+POS and EVL+ITC exhibited superior in vitro synergistic efficacy, respectively inhibiting the growth of 64% (14/22) and 59% (13/22) of tested strains. In contrast, the growth of just 9% (2/22) of tested strains was inhibited by a combination of EVL+AMB, and no synergistic efficacy was observed for the combination of EVL+VRC.

Discussion: Overall, these findings indicate that EVL holds promise as a novel drug that can be synergistically combined with extant antifungal drugs to improve their efficacy, thereby aiding in the treatment of CBM.

Citing Articles

Antimicrobial peptide AMP-17 induces protection against systemic candidiasis and interacts synergistically with fluconazole against biofilm.

Sun C, Zhu L, Yang L, Tian Z, Jiao Z, Huang M Front Microbiol. 2024; 15:1480808.

PMID: 39552641 PMC: 11564183. DOI: 10.3389/fmicb.2024.1480808.

Development of PCR-Multiplex Assays for Identification of the Herpotrichiellaceae Family and Agents Causing Chromoblastomycosis.

Sousa G, De Oliveira R, Souza A, Monteiro R, Santo E, Franco Filho L J Fungi (Basel). 2024; 10(8).

PMID: 39194874 PMC: 11355602. DOI: 10.3390/jof10080548.

Identification of Chromoblastomycosis and Phaeohyphomycosis Agents through ITS-RFLP.

Sousa G, De Oliveira R, De Souza A, Monteiro R, Santo E, Franco Filho L J Fungi (Basel). 2024; 10(2).

PMID: 38392831 PMC: 10890301. DOI: 10.3390/jof10020159.

References

Daboit T, Magagnin C, Heidrich D, Antochevis L, Vigolo S, Meirelles L . In vitro susceptibility of chromoblastomycosis agents to five antifungal drugs and to the combination of terbinafine and amphotericin B. Mycoses. 2013; 57(2):116-20. DOI: 10.1111/myc.12111. View

Kumari S, Kumar M, Esquivel B, Wasi M, Pandey A, Khandelwal N . Unmasking of CgYor1-Dependent Azole Resistance Mediated by Target of Rapamycin (TOR) and Calcineurin Signaling in Candida glabrata. mBio. 2022; 13(1):e0354521. PMC: 8764518. DOI: 10.1128/mbio.03545-21. View

Lupi O, Tyring S, McGinnis M . Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol. 2005; 53(6):931-51, quiz 952-4. DOI: 10.1016/j.jaad.2004.10.883. View

Heidrich D, Pagani D, Koehler A, Alves K, Scroferneker M . Effect of Melanin Biosynthesis Inhibition on the Antifungal Susceptibility of Chromoblastomycosis Agents. Antimicrob Agents Chemother. 2021; 65(8):e0054621. PMC: 8284458. DOI: 10.1128/AAC.00546-21. View

So Y, Lee D, Idnurm A, Ianiri G, Bahn Y . The TOR Pathway Plays Pleiotropic Roles in Growth and Stress Responses of the Fungal Pathogen . Genetics. 2019; 212(4):1241-1258. PMC: 6707454. DOI: 10.1534/genetics.119.302191. View

Seas C, Legua P . Mycetoma, chromoblastomycosis and other deep fungal infections: diagnostic and treatment approach. Curr Opin Infect Dis. 2022; 35(5):379-383. DOI: 10.1097/QCO.0000000000000870. View

Bastidas R, Reedy J, Morales-Johansson H, Heitman J, Cardenas M . Signaling cascades as drug targets in model and pathogenic fungi. Curr Opin Investig Drugs. 2008; 9(8):856-64. PMC: 2715221. View

Chen S, Lewis R, Kontoyiannis D . Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species. Virulence. 2011; 2(4):280-95. PMC: 3173675. DOI: 10.4161/viru.2.4.16764. View

Sousa I, Mello T, Pereira E, Granato M, Alviano C, Santos A . Biofilm Formation by Chromoblastomycosis Fungi and : Involvement with Antifungal Resistance. J Fungi (Basel). 2022; 8(9). PMC: 9504689. DOI: 10.3390/jof8090963. View

10.

Jiang H, Xiong J, Tan L, Jin P, Sun Y, Yang L . Interactions of Antifungal Agents and Everolimus Against Species. Front Cell Infect Microbiol. 2022; 12:936814. PMC: 9294350. DOI: 10.3389/fcimb.2022.936814. View

11.

Blenis J . TOR, the Gateway to Cellular Metabolism, Cell Growth, and Disease. Cell. 2017; 171(1):10-13. DOI: 10.1016/j.cell.2017.08.019. View

12.

Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015; 387(10022):968-977. PMC: 6063317. DOI: 10.1016/S0140-6736(15)00817-X. View

13.

Wang Z, Liu M, Liu L, Li L, Tan L, Sun Y . The Synergistic Effect of Tacrolimus (FK506) or Everolimus and Azoles Against and Species and . Front Cell Infect Microbiol. 2022; 12:864912. PMC: 9046971. DOI: 10.3389/fcimb.2022.864912. View

14.

Fingar D, Blenis J . Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004; 23(18):3151-71. DOI: 10.1038/sj.onc.1207542. View

15.

Babiker H, Karass M, Recio-Boiles A, Chandana S, McBride A, Mahadevan D . Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs. 2019; 28(7):583-592. PMC: 6681663. DOI: 10.1080/13543784.2019.1632289. View

16.

Yamamoto K, Uda A, Mukai A, Yamashita K, Kume M, Makimoto H . Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition. J Exp Clin Cancer Res. 2014; 32:83. PMC: 3874739. DOI: 10.1186/1756-9966-32-83. View

17.

Li Y, Xiao J, de Hoog G, Wang X, Wan Z, Yu J . Biodiversity and human-pathogenicity of and relatives in . Persoonia. 2017; 38:1-19. PMC: 5645179. DOI: 10.3767/003158517X692779. View

18.

Ahmed S, Bonifaz A, Gonzalez G, Moreno L, Silva N, A Vicente V . Chromoblastomycosis Caused by -Proven Cases from Mexico. J Fungi (Basel). 2021; 7(2). PMC: 7910919. DOI: 10.3390/jof7020095. View

19.

Mossmann D, Park S, Hall M . mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018; 18(12):744-757. DOI: 10.1038/s41568-018-0074-8. View

20.

Najafzadeh M, Sun J, A Vicente V, Klaassen C, Bonifaz A, Gerrits van den Ende A . Molecular epidemiology of Fonsecaea species. Emerg Infect Dis. 2011; 17(3):464-9. PMC: 3165995. DOI: 10.3201/eid1703.100555. View